Volume 3, Issue 10, 2025

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

# BETA-THALASSEMIA: CURRENT PERSPECTIVES ON PATHOGENESIS, SCREENING, AND TREATMENT

**Bisma Akhtar[1], Nabia Azam[2], Shahid Mahmood[*3], Malik Ilyas[4], Madeeha Zia[5], Bushra Aslam[6]**

[1,2,*3,4,5,6]*Department of Zoology, University of Gujrat, Gujrat 50700, Pakistan*

[*3]shahid.mahmood@uog.edu.pk

**DOI:** https://doi.org/10.5281/zenodo.18165630

**Keywords**

*Beta-thalassemia, beta (β) globin, Middle East, Gene Therapy, MCV, MCH.*

**Article History**

*Received: 11 October 2025*
*Accepted: 21 November 2025*
*Published: 31 December 2025*

**Copyright** @Author

**Corresponding Author: ***
**Shahid Mahmood**

## Abstract

*Beta thalassemia represents one of the maximum not unusual and severe inherited blood disorders affecting the population of Pakistan. The disorder burden is intensified by way of an excessive prevalence of providers, massive consanguineous marital practices, and barriers in organized screening and healthcare offerings as an end result Pakistan stories a great medical, social, and financial effect from both transfusion established and non-transfusion sorts of beta thalassemia. This review brings collectively modern day know how on ailment distribution, genetic mechanisms, clinical manifestations, diagnostic strategies, treatment alternatives, preventive techniques, healthcare gadget limitations, and sensible hints that are applicable to the countrywide healthcare putting of Pakistan.*

## INTRODUCTION

Thalassemia syndromes are hereditary blood problems that disrupt the regular manufacturing of hemoglobin, an essential protein observed in red blood cells that includes oxygen from the lungs to physical tissues (Weatherall & Clegg, 2001). Crimson blood cells lose their balance and efficiency, which results in their premature destruction, at the same time as hemoglobin synthesis is decreased or abnormal (Cappellini et al., 2018). In the long run, this approach consequences in chronic anemia and insufficient oxygen delivery is the reason some of the signs and symptoms and indicators discovered in affected people (Galanello & Origa, 2010).

Hemoglobin consists of alpha (α) and beta (β) globin chains, and their balanced formation is important for healthful purple blood mobile feature (Hoffbrand et al., 2019). Thalassemia develops whilst the synthesis of one sort of globin chain is decreased relative to the alternative. In this foundation, the ailment is labeled into alpha-thalassemia and beta-thalassemia (Weatherall, 2010). Among the ones, beta-thalassemia is typically associated with greater extreme scientific effects and often requires non-stop medical manipulate (Cappellini et al., 2014).

A high-quality function of thalassemia syndromes is the massive variation in disorder severity (Galanello & Origa, 2010). Some people inherit the genetic alteration without displaying substantive signs and symptoms, while others enjoy extreme anemia early in life (Taher et al., 2018). This extensive variety of results is stimulated through the specific genetic mutation concerned, inheritance patterns, and the presence of additional genetic modifiers which could lessen or worsen disease expression (Weatherall,

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

2010). Therefore, thalassemia is satisfactory understood as a collection of associated situations in place of a single uniform sickness (Cao & Galanello, 2010).

**Historical perspective:**

The medical know how of thalassemia has evolved step by step during the last century. The circumstance changed into first certainly described in 1925 by Dr. Thomas Cooley, who documented children stricken by excessive anemia, splenic growth, and atypical bone improvement (Cooley & Lee, 1925). First of all, this sickness become referred to as Cooley's anemia, and its genetic origin became now not but identified (Weatherall & Clegg, 2001).

As studies stepped forward, it became glaring that the sickness happened greater frequently in populations dwelling across the Mediterranean region. This statement brought about the term thalassemia, derived from the Greek word Thalassa, which means sea (Weatherall, 2010). For decades, thalassemia became mistakenly stressed with dietary anemia, specially iron deficiency, which ended in inappropriate treatment and aggravating of iron overload in affected sufferers (Hoffbrand et al., 2019).

**Global prevalence and geographic spread:**

Areas that traditionally had excessive malaria occurrence which include the Mediterranean, Middle East, South Asia, and Southeast Asia keep to record the best incidence of the disease (Cao & Galanello, 2010). Heterozygous companies of thalassemia genes traditionally had some safety towards malaria, permitting these mutations to persist and spread over generations (Kwiatkowski, 2005).

Inside the Mediterranean basin, mainly in southern ECU international locations and islands, beta-thalassemia has long been a substantial fitness concern (Cao & Kan, 2013). Within the center East high occurrence is further amplified by way of traditions of marriage inside extended families (Hamamy, 2012). South Asia, with its huge and various population, contributes extensively to the range of latest instances every yr (Modell & Darlison, 2008). Southeast Asia also reviews great incidence, frequently complicated via the presence of a couple of hemoglobin issues in the same populations (Fucharoen & Weatherall, 2012).Worldwide migration has more and more spread beta-thalassemia to areas previously taken into consideration low-hazard (Vichinsky, 2018). Nations in Europe, North the us, and Australia are actually experiencing a upward push in patients, necessitating healthcare systems to adapt by way of growing specialized diagnostic and treatment offerings (Cappellini et al., 2020).

**Regional and Country Specific Data:**

The range of humans sporting beta-thalassemia genes is a long way larger than those diagnosed with the sickness (Modell & Darlison, 2008). Most carriers are healthful and blind to their genetic popularity until habitual blood checking out or own family screening reveals it (WHO, 2021). This hidden populace of vendors gives a first-rate impediment to prevention, as couples who're both vendors can unknowingly bypass the condition to their children (Cao & Galanello, 2010). Provider incidence can range widely inside the same United States of America (Weatherall, 2010). Positive ethnic corporations, rural groups, or isolated populations often have better quotes due to shared ancestry (Hamamy, 2012). Misdiagnosis as moderate iron deficiency anemia is not unusual, resulting in inappropriate treatment and not on time genetic counseling (Cappellini et al., 2020).

**Disease Burden in Low and Middle Income Countries:**

In a lot of those international locations, normal blood transfusions, iron chelation remedy, and worry tracking are inconsistent or unavailable (WHO, 2021). As an end result, sufferers regularly enjoy not on time care, increasing the danger of excessive complications at a younger age (Cappellini et al., 2020). Admission to specialized healthcare centers is normally restricted to urban regions, leaving rural patients underserved (Vichinsky, 2018).

**Socioeconomic and Healthcare Impact:**

Handling beta-thalassemia is financially disturbing because of the lifelong nature of treatment (Cappellini et al., 2020). The cumulative value of regular transfusions, chelation medicinal drugs,

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

laboratory monitoring, and clinic visits is giant (Modell & Darlison, 2008). Additionally, long-time period care costs place a heavy burden on country wide healthcare structures, underlining the importance of preventive techniques which include provider screening and genetic counseling, which might be a ways greater fee-powerful in the end (Cao & Kan, 2013).

**Molecular genetics of Beta-thalassemia:**

In line with Cao and Galanello (2010), beta-thalassemia is a hereditary blood sickness caused by changes within the β-globin gene that result in reduced or nonexistent production of β-globin chains. A good way to bring together person hemoglobin (HbA), those chains need to pair with α-globin chains (Weatherall & Clegg, 2001). This imbalance leads to continual anemia, early erythrocyte destruction, and useless manufacturing of red blood cells (Rund & Rachmilewitz, 2005).

**Types of β Globin Gene Mutations:**

Beta-thalassemia arises from an expansion of mutations in the β-globin gene, each affecting protein manufacturing differently (Cao & Galanello, 2010). Mutations are widely divided into $\beta^0$ mutations, which completely prevent β-globin manufacturing, and $\beta^+$ mutations, which partly lessen it (Weatherall & Clegg, 2001). $B^0$ mutations frequently arise because of nonsense mutations, frame shift insertions or deletions, or large gene deletions (Rund & Rachmilewitz, 2005). People sporting $\beta^0$ mutations usually develop extreme, transfusion-based beta-thalassemia main in the course of infancy (Cappellini et al., 2020). In contrast, $\beta^+$ mutations generally contain promoter regions or splice sites, permitting some β-globin to be produced (Thein, 2013). Those individuals might also expand intermediate kinds of the sickness that are much less extreme and often require intermittent transfusions (Weatherall, 2010).

**Inheritance pattern:**

In households where in both parents are vendors, each baby has a 25 % chance of developing beta-thalassemia essential, a 50 % risk of being a service, and a 25 % threat of being unaffected (WHO, 2021). The genotype phenotype relationship depends on several factors (Thein, 2013). Homozygous $\beta^0$ mutations usually reason extreme, transfusion-based anemia, even as $\beta^+$ or compound heterozygotes frequently have milder disorder (Cappellini et al., 2020). Modifier genes play an critical function; higher ranges of fetal hemoglobin (HbF) can in part catch up on deficient β-globin, decreasing anemia severity and transfusion needs (Bauer et al., 2012). Co-inheritance of α-thalassemia also can enhance the globin chain stability and clinical outcomes (Rund & Rachmilewitz, 2005).

**Ineffective Erythropoiesis:**

Useless erythropoiesis takes place while the bone marrow is actively producing pink blood cells, however maximum die prematurely because of α-globin toxicity (Rund & Rachmilewitz, 2005).

Bone marrow growth persistent anemia alerts the body to supply greater crimson blood cells, resulting in enlarged bone marrow, specifically in the skull and long bones, causing skeletal deformities (Cappellini et al., 2020).

**Extra medullary hematopoiesis:**

Whilst the marrow can't meet the demand, crimson blood cell production shifts to different organs like the spleen and liver, causing organ enlargement. (Taher et al., 2018).

**Inflammatory Outcomes:**

Hyperactive marrow releases inflammatory alerts and increases oxidative strain, similarly adverse purple cells and contributing to fatigue, weakness, and systemic headaches (Musallam et al., 2012).

**Classification of Beta Thalassemia:**

Beta thalassemia is an inherited blood sickness that influences the body's potential to supply hemoglobin, the protein in red blood cells responsible for transporting oxygen (Weatherall & Clegg, 2001). Due to deficient or absent β-globin chains, pink blood cells are ineffective, resulting in anemia and more than a few fitness complications (Cao & Galanello, 2010). Through the years, doctor and researchers have identified that the sickness manifests along a spectrum of severity, from slight, nearly invisible symptoms and signs to severe conditions requiring lifelong hospital therapy (Taher

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

et al., 2018).This classification is extra than a scientific label it permits physicians decide tracking strategies, suitable remedy, and steerage for families about the probability of passing the scenario to their children (Cappellini et al., 2020).

**Beta Thalassemia Minor:**

Beta-thalassemia minor, also referred to as the provider nation, happens when an individual inherits one regular β-globin gene and one defective gene (Cao & Galanello, 2010). The general public with this form are usually healthy and might never comprehend they carry the gene (Weatherall, 2010). Laboratory assessments frequently screen microcytic, hypochromic red blood cells, and hemoglobin electrophoresis can also display a modest boom in $HbA_2$ (Rund & Rachmilewitz, 2005). Genetic testing can pick out the mutation that is useful in populations with excessive disease prevalence (WHO, 2021).If each dad and mom deliver the trait, every baby has a 25% chance of inheriting beta-thalassemia fundamental, making service identity critical for prevention (Cappellini et al., 2020).

**Beta thalassemia intermediate:**

Beta-thalassemia intermediate represents an intermediate form of the disorder, commonly as a result of mutations allowing partial β globin production (Taher et al., 2018). Symptoms vary widely and can appear in late youth or early life (Thein, 2013).Splenomegaly, bone marrow enlargement, gallstones, and iron overload may additionally arise even without ordinary transfusions (Musallam et al., 2012).

**Beta Thalassemia Major:**

Signs normally emerge inside the first year of lifestyles (Cao & Galanello, 2010).Normal blood transfusions and iron chelation remedy are required for survival (Cappellini et al., 2020). Bone marrow transplantation offers an ability treatment, whilst gene remedy is a rising remedy alternative (Nienhuis & men and women, 2021).

**Clinical Manifestations of Beta-Thalassemia:**

Hemoglobin is critical for carrying oxygen at some point of the body, so any deficiency can bring about insufficient oxygen shipping, leading to a huge spectrum of symptoms. Expertise the clinical capabilities aids clinicians in early analysis and allows for more powerful control to improve each longevity and exceptional of lifestyles (Taher et al., 2021).

**Hematologic Abnormalities:**

Anemia is the maximum distinguished and steady symptom of beta-thalassemia. In extreme office work, hemoglobin tiers can drop considerably, inflicting patients to enjoy continual fatigue, pallor, shortness of breath, and dwindled exercising tolerance. Toddlers with beta-thalassemia most important may moreover appear inclined, feed poorly, and display behind schedule boom, regularly prompting early medical evaluation (Origa, 2017).

Laboratory investigations screen small, faded purple blood cells (microcytosis and hypochromia), sizeable variability in cell size and shape (anisopoikilocytosis), and the presence of goal cells, which are precise for this disease.The bone marrow compensates for the anemia through producing big numbers of immature red blood cells, ensuing in an expanded reticulocyte depend. From time to time, platelet and white blood cellular counts will also be barely accelerated as a part of the compensatory reaction (Hoffbrand et al., 2019). The continued destruction of purple blood cells can motive jaundice, and over time, patients are at threat for developing gallstones. Hemoglobin studies normally show extended tiers of fetal hemoglobin (HbF) and $HbA_2$, which are valuable diagnostic markers and assist differentiate beta-thalassemia from distinctive anemias (Cao & Galanello, 2010).

**Multi Organ Involvement:**

Beta-thalassemia influences a couple of organs past the blood and bones. The spleen is often enlarged due to extended red blood cellular destruction, leading to belly discomfort, early satiety, and aggravating anemia. In some cases, splenectomy may be important, although it consists of an extended danger of infections (Taher et al., 2018).

**Complete Blood Count (CBC) Findings:**

Initial laboratory assessment usually indicates long-standing anemia characterized by significantly reduced hemoglobin concentration along with lowered hematocrit levels. Red blood cell indices

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

such as mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) are consistently decreased, reflecting a microcytic and hypochromic pattern. Interestingly, despite low hemoglobin levels, the total red blood cell count may remain normal or even increased a distinguishing feature that helps differentiate thalassemia from iron deficiency anemia (Greer et al., 2018; Hoff brand & Moss, 2019).

**Red Cell Indices:**

Detailed evaluation of erythrocyte indices generally shows persistently low MCV and MCH values, while red cell distribution width (RDW) often remains within normal limits. This indicates uniform microcytosis rather than marked variation in cell size, a finding that contrasts with iron deficiency anemia where RDW is usually elevated (Weather all & Clegg, 2001).

**Peripheral Blood Smear:**

**Target Cells:**

Examination of a peripheral blood smear frequently demonstrates the presence of target cells. These cells arise due to an imbalance between the red cell membrane surface area and intracellular hemoglobin content and are commonly associated with disorders of abnormal hemoglobin production (Greer et al., 2018).

**Anisopoikilocytosis:**

Pronounced variation in red blood cell size (anisocytosis) and shape (poikilocytosis) is commonly observed. Other associated features may include nucleated red cells, teardrop-shaped erythrocytes, and basophilic stippling, all of which reflect ineffective erythropoiesis occurring within the bone marrow (Hoffbrand & Moss, 2019).

**Hemoglobin Electrophoresis:**

Hemoglobin electrophoresis is a key diagnostic tool that separates hemoglobin fractions based on their electrical charge and mobility. This technique allows identification of abnormal hemoglobin variants and aids in confirming the specific type of thalassemia present (Weatherall & Clegg, 2001).

**Hematological Investigations:**

The first sign you usually notice in lab tests is anemia. Patients keep showing low hemoglobin and hematocrit. If you look at the red blood cell indices, especially MCV and MCH, they're way below normal classic microcytic, hypochromic anemia. Even though the hemoglobin's down, the actual red cell count often looks normal, or sometimes even higher than usual. This detail matters because it helps set thalassemia apart from iron deficiency anemia, where the red cell count drops.

**Diagnostic Evaluation:**

Over time, these numbers barely budge. Both MCV and MCH stay low, and RDW typically sits in the normal range. That tells you the red cells are all about the same size, which isn't what you see in iron deficiency there, cell sizes are all over the place (Hoffbrand & Moss, 2019; Weatherall & Clegg, 2001).

**Peripheral Blood Smear Findings:**

Take a look at the peripheral smear, and you'll find more clues. Target cells pop up a lot they show up when there's not enough hemoglobin for the red cell's surface area. Spotting these really points you toward a hemoglobin synthesis problem. You'll also see red cells that vary in size and shape (anisocytosis and poikilocytosis). Other features, like nucleated red cells, teardrop shapes, or basophilic stippling, can show up too. Basically, the bone marrow's in overdrive, just trying to keep up (Greer et al., 2018).

**Hemoglobin Analysis:**

If you think thalassemia's in the picture, you need hemoglobin electrophoresis. This test sorts out different types of hemoglobin by seeing how they move in an electric field. That way, you can catch any unusual patterns and nail down exactly which kind of thalassemia it is. Patients often have more fetal hemoglobin (HbF) than normal to make up for faulty globin chain production. If you see high hemoglobin $A_2$, that's a big clue for beta-thalassemia trait and is a pretty reliable marker (Cappellini et al., 2021).

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

**Molecular and Prenatal Diagnosis:**

Genetic testing is key for confirming thalassemia. DNA tests like PCR can pick up specific globin gene mutations, letting you diagnose the condition, spot carriers, and offer accurate genetic counseling (Weatherall and Clegg, 2001). For families at risk, prenatal tests like chorionic villus sampling or amniocentesis can spot affected fetuses early in pregnancy. That way, parents have time to plan and make informed choices (Weatherall & Clegg, 2001).

**Differential Diagnosis:**

Thalassemia and iron deficiency anemia can look almost identical under a microscope both have small, pale red cells. Iron studies help you tell them apart. Iron deficiency anemia comes with low serum ferritin and low iron stores, but thalassemia usually shows normal or even high iron levels (Hoffbrand, 2019; Greer et al., 2018). Other hemoglobin disorders, like alpha-thalassemia, can look similar during detailed hemoglobin analysis and genetic studies. Sideroblastic anemia comes from faulty heme synthesis and shows ring sideroblasts in the bone marrow. Iron piles up inside mitochondria, not from transfusions, which helps you tell it apart from thalassemia (Hoffbrand & Moss, 2019; Greer et al., 2018).

**Management Strategies:**

**Blood Transfusion Therapy:**

If the patient has a severe form of thalassemia, regular blood transfusions are a must to keep hemoglobin levels high enough for growth and daily living. Most guidelines aim for hemoglobin above 9, 10 g/dl, but the exact schedule depends on the person. Transfusions help get oxygen where it needs to go and calm down the overactive bone marrow. Still, they bring their own set of problems iron overload, transfusion reactions, and the risk of infections (Cappellini et al., 2021).

**Iron Related Organ Damage:**

Hepatic complications excess iron is mainly stored in the liver. Over time, this may cause liver swelling and permanent liver Injury .Iron overload affects endocrine glands. Endocrine complications High iron levels can damage hormone-producing glands. This may result in slow growth, late puberty, diabetes, and hormonal imbalance.

**Infectious complications:**

People with beta-thalassemia are more likely to develop infections. Due to frequent transfusions and medical procedures. This increased risk is linked to repeated transfusions and hospital visits. Infections may be transmitted through blood. In some cases, infections can be spread through blood transfusions. This happens despite careful screening of donated blood.

**Psychosocial and quality of life issue:**

Beta-thalassemia also affects a person's emotional and mental health. Ongoing treatment often leads to stress, anxiety, and emotional exhaustion. Education, employment, and social life are often interrupted. This makes it harder for patients to adjust socially.

**Beta Thalassemia in Special Populations:**

**Children and adolescents**

Children show slow physical growth: Children with beta-thalassemia usually experience delayed physical growth. The onset of puberty is often delayed. This delay is mainly caused by hormonal problems and chronic illness.

**Pregnancy and beta thalassemia**

Pregnancy in women with beta-thalassemia requires close medical supervision. The mother may suffer from severe anemia and heart related complications. The unborn baby may inherit beta thalassemia or have low birth weight .with regular checkups, planned transfusions, and specialist care, pregnancy can be managed safely.

**Prevention and Control:**

Prevention is the most effective way to control beta-thalassemia .Carrier screening helps detect individuals who carry the thalassemia gene .Genetic counseling helps families understand future risks and options. Prenatal tests can identify beta-thalassemia in the fetus at an early stage. Final decisions are influenced by ethical, cultural, and religious beliefs.

**Research Metrics Analysis:**

They proposed that similar Scientometric research, including the current one, may use their results as a

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

baseline or reference. Gupta and Gupta used the Scopus database to examine 1,030 thalassemia research articles that were published globally between 2008 and 2017. They looked at how quickly research was expanding, how much each nation produced, how frequently papers were mentioned, the degree of international cooperation, and the most influential and prolific subjects, organizations, and writers.From 2006 to 2016, Yaminfirooz and associates examined Iranian thalassemia publications that were indexed in the Web of Science. They emphasized author-institution cooperation. According to their findings, researchers were not well connected since collaboration networks were weak. They came to the conclusion that, in comparison to other scientific domains, collaboration in thalassemia research remained restricted, despite an increase in scientific output and cooperation (.Hossain, S., & Batcha, M. S. 2021).

A scientometric review of works on brownfield studies (reusing polluted land) from 1995 to 2017 was carried out by Lin, Zhu, Ahmad, and Han. After analyzing 630 publications, they discovered that study themes evolved over time, moving from soil remediation techniques to sustainable rebuilding. The United States, England, Canada, Germany, and China were among the nations that made significant contributions (. Saddam Hussain & M. Sadik Batch 2021).

Between 2011 and 2017, Batch and Ahmad examined two scholarly publications: the Pakistan Journal of Library and Information Science (PJLIS) and the Indian Journal of Information Sources and Services (IJISS). They looked at authorship patterns, collaboration, document length, publication trends, and keyword usage. With very little international cooperation, the majority of papers in PJLIS were authored by Pakistani authors and the majority of papers in IJISS were produced by Indian academics (. Saddam Hussain & M. Sadik Batch 2021). Indicators including the H-index, G-index, M-index, A-index, and R-index were used to gauge research performance. They discovered that some indicators, particularly the G and R indexes, had extremely strong correlations. Major universities in Tehran, Tabriz, and Mashhad were connected to the majority of the top-ranked research centers (.Hossain, S., & Batcha, M. S. 2021).

**Clinical trials update in new treatments of B-thalassemia:**

A broad class of proteins known as the TGF-β (transforming growth factor-beta) superfamily aids in regulating the growth, development, and operation of cells. This family consists of TGF-β. Bone morphogenetic proteins, or BMPs, Growth and differentiation factors, or GDFs, Activins. These proteins function by binding to specific cell receptors. Through a process known as the SMAD pathway, which regulates cell behavior, these receptors transmit signals inside the cell.The TGF-β superfamily is important for, Differentiation and growth of cells, keeping tissues healthy, Bone development, Hematopoiesis, the process of making blood cells, particularly red blood cells. These proteins have various effects on the formation of red blood cells, according to laboratory research: Certain members, such as TGF-β and BMP4, aid in the development of precursors for red blood cell. Others (such as GDFs and Activins) halt or slow the formation of red blood cells, for optimal blood formation, these signals must be properly balanced.Later stages of red blood cell maturation are prevented by activins and GDFs .This stopping action is normal and aids in the timely termination of red blood cell production. Additionally, activins have an impact on bones by promoting bone deterioration and decreasing bone growth. Activins A, Activins B, and Activins AB are the three different types of activins.Act RIIA and Act RIIB are their two primary receptors. GDF11 is also bound by the receptor Act RIIB (Alexandros. M 2017).

Red blood cell synthesis is poor in conditions such as β-thalassemia. Before developing into healthy red blood cells, far too many immature cells perish. Red blood cell maturation can be aided by blocking GDFs and Activins. This can alleviate anemia brought on by insufficient synthesis of red blood cells. Scientists developed special drugs called ligand traps to block activins and GDFs. This are modified receptors that “trap” the harmful proteins before they reach real cell receptors. They are made by joining part of the activins receptor with part of an antibody (IgG), making them more effective and longer-lasting. By trapping activins and GDFs, they stop the SMAD signaling pathway. When β-thalassemia mice were used to test RAP-011 and

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

RAP-536, they: Better anaemia decreased spleen enlargement (splenomegaly) decreased iron overload, reduced the accumulation of dangerous proteins in red blood cells, Decreased oxidative damage, aided the survival and maturation of immature red blood cells, Reduced bloodstream breakdown of red blood cells RAP-011 stopped immature blood cells from dying and decreased GDF11activity Overactive SMAD signaling was decreased by RAP-536 (Alexandros M 2017).

**Advances in gene therapy:**

Reduced ($\beta^+$) or absent ($\beta^+$) synthesis of hemoglobin's β-globin chain is the cause of β thalassemia. As a result, growing red blood cells have too many free α-globin chains and low amounts of typical buildup of these α-globin chains harms the cells, causing adult hemoglobin (HbA).

**Dystery thropoiesis**

The improper generation of red blood cells and a reduction in the lifespan of circulating red blood cells, both of which contribute to severe anemia. Regular red-cell transfusions are necessary to maintain appropriate hemoglobin levels and enhance survival in the most severe form, transfusion-dependent β thalassemia. However, iron overload brought on by repeated transfusions can seriously harm the liver, heart, and endocrine organs. The only proven treatment for β thalassemia in children is allogeneic hematopoietic stem cell transplantation. When compared to traditional transfusion-based therapy, this strategy can improve quality of life and achieve overall survival rates of over 90% and β-thalassemia-free survival rates above 83%. Despite these advantages, its usage is constrained by serious hazards. Such as graft rejection and graft-versus-host disease, as well as the challenge of locating qualified donors' different approach that does not require a compatible donor is hematopoietic stem-cell gene therapy. This method removes immunological difficulties by introducing a functioning β globin gene into the patient's own stem cells. Hematopoietic stem and progenitor cells are collected, genetically altered in a lab, and then rein fused into the patient following my elaborative conditioning (Payen. E, 2022).

A gene therapy product called betibeglogene autotemcel (beti-cel) was created to treat transfusion-dependent β-thalassemia. The BB305 lentiviral vector, which carries a modified β globin gene (βT87Q) capable of producing functional hemoglobin, is used to transduce autologous $CD34^+$ stem cells. Due to low gene-transfer efficiency, earlier vectors were not very efficient; however, BB305 greatly enhanced hemoglobin synthesis and stem-cell transduction. 85% of patients with $\beta^+$ transfusion-dependent β-thalassemia attained transfusion independence in phase 1-2 clinical trials, sustaining hemoglobin levels of at least 9 g/dl for a minimum of 12 months. Hemoglobin levels after treatment varied from 9.1 to 13.2 g/dl, indicating that beta cell gene therapy is a promising long-term treatment option for many individuals with β thalassemia and can significantly reduce or eliminate the requirement for transfusions (Payen E, 2022).

**Therapies in beta thalassemia:**

As treatment choices have improved over time, patients with β thalassemia have seen a steady improvement in their quality of life. However, as was previously said, there are still a lot of serious hazards and restrictions associated with many of the existing therapeutic approaches. Recent years have seen significant advancements in molecular biology and a better understanding of the disease's basic causes and clinical characteristics, which have prompted a great deal of research into the creation of novel treatments for β thalassemia. Many significant discoveries have been made within the last thirty years, which have resulted in the development of numerous innovative therapeutic strategies. Based on how they target the underlying disease mechanisms, these emerging therapies can be broadly classified into three main categories: treatments intended to correct the imbalance in globin chain production, strategies aimed at correcting ineffective erythropoiesis (IE), and approaches designed to reduce iron overload (Borg. J, 2022).

**Novel pharmacological treatments:**

One of the main characteristics of β thalassemia is ineffective erythropoiesis, which is defined by aberrant elytroid precursor cell formation and maturation as well as increased destruction of immature red blood cells. Only a tiny percentage of elytroid cells successfully develop into functional red

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

blood cells, despite the fact that they multiply and survive in greater quantities. This mechanism causes the bone marrow to enlarge, erythropoietin tissue to grow outside the bone marrow, especially in the chest and Para spinal areas, and persistent anemia, among other significant problems in β thalassemia. Understanding the molecular and cellular mechanisms underlying ineffective erythropoiesis has advanced significantly over the past ten years, leading to the creation of numerous novel medications and therapeutic approaches that are presently undergoing preclinical research and clinical trials (Borg, J. 2022).

**Challenges in resources limited setting:**

To assist governments and policymakers in making wise health decisions, precise information is desperately needed. The majority of politicians lack public health training and typically has very little knowledge about uncommon, hereditary, or inherited illnesses like thalassemia. They must comprehend the nature of the illness, how it develops over time, and how therapy can enhance patient outcomes in order to develop effective health policies. They must also understand that thalassemia care necessitates a variety of therapeutic components, as well as trustworthy diagnostic instruments and long-term monitoring methods. In order for national healthcare budgets to incorporate these requirements, they must be well understood. Only with accurate data on the number of patients, the number of new patients anticipated annually, and the number of patients who pass away can services be properly planned. Epidemiological data is the source of this kind of information. The Thalassemia International Federation (TIF) gathers patient data through published reports and local visits when trustworthy national records are not available. More than 520,000 people with beta thalassemia syndromes are thought to currently reside in 69 countries, according to the information that is currently accessible. Countries like China and Cambodia, where thalassemia is predicted to be widespread but no accurate numbers are available, are not included in this figure. In addition to more births, population migration and higher survival rates can also lead to an increase in the number of patients. The Hardy-Weinberg principle can be used to estimate the number of impacted newborns from carrier rates; however, these carrier rates can vary greatly even within the same country and are frequently based on small or biased population samples (Angastiniotis, M. 2024).

**Access to diagnosis and treatment cost and infrastructure limitations**:

While the fundamentals of thalassemia treatment are simple to understand, individuals and healthcare systems find it difficult to put them into practice. The effectiveness of applying evidence-based methods and the consistency with which internationally recognized treatment protocols are adhered to have a significant impact on patient outcomes. Crucially, the quality, organization, and continuity of care are more important factors in determining successful outcomes than a nation's income level. Inadequate resources, conflicting health agendas, and a lack of experience among medical experts are frequently the causes of subpar outcomes. On the other hand, results can be roughly classified into unfavorable situations. Children with TDT frequently pass away at a young age when there is no treatment or very inadequate treatment, such as irregular or insufficient blood transfusions. Depending on the genetic type of the disease, people with NTDT may not die right away, but issues progressively build up over time, resulting in poor health, a lower quality of life, and a shorter survival. In low and middle-income nations, as well as during times of political unrest, violence, or economic collapse, this condition is most frequently observed. .Partial use of treatment standards and recommendations is an increasingly prevalent worldwide situation. In these situations, people may live for 20 to 40 years, but their liver, heart, and endocrine systems become increasingly problematic. As people age, their quality of life deteriorates, disease-related morbidity increases, and healthcare costs grow. The majority of thalassemia patients globally are impacted by this ineffective and resource-wasting care strategy, which reflects uneven access to thorough, high-quality therapy (Angastiniotis, M. 2024).

**Conclusion:**

A significant inherited blood condition, beta thalassemia still poses a serious threat to public

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

health, particularly in regions with high incidence rates. The disorder is caused by defective beta-globin chain synthesis, which leads to persistent anemia and a wide range of symptoms from mild to severe, transfusion structured illness. Regardless of advancements in genetic research and medical treatment, beta thalassemia is a chronic illness that profoundly affects the physical health, psychological well-being, and social lives of patients and their families. Treatment advancements, particularly iron chelation therapy, regular blood transfusions, and multidisciplinary supportive care, have significantly improved survival and quality of life for people with beta thalassemia. However, these treatments are not curative and necessitate close supervision, lifetime adherence, and substantial medical expenditures. Long-term effects include iron overload, heart disease, and endocrine issues continue to be the most difficult circumstances. Hematopoietic stem cell transplantation offers a potential solution, but its use is limited due to donor scarcity, high costs, and related risks. Treatment advancements, particularly iron chelation therapy, regular blood transfusions, and multidisciplinary supportive care, have significantly improved survival and quality of life for people with beta thalassemia. However, these treatments are not curative and necessitate close supervision, lifetime adherence, and substantial medical expenditures. Long-term effects include iron overload, heart disease, and endocrine issues continue to be the most difficult circumstances. Hematopoietic stem cell transplantation offers a potential solution, but its use is limited due to donor scarcity, high costs, and related risks.

## REFERENCES

Angastiniotis, M. (2024). Beta thalassemia: Looking to the future, addressing unmet needs and challenges. Annals of the New York Academy of Sciences, 1532(1), 63-72.

Bulletin of the World Health Organization. 2008.

Cao, A., & Kan, Y. W. (2013). The prevention of thalassemia. *Cold Spring Harbor perspectives in medicine*, *3*(2), a011775.

Cappellini, M. D., Cohen, A., Porter, J., Taher, A., & Viprakasit, V. (Eds.). (2014). Guidelines for the management of transfusion dependent thalassaemia (TDT).

David Weatheral, J., & Clegg, J. L. (2001). The Thalassaemia Syndromes, 4th.

Fucharoen, S., & Weatherall, D. J. (2012). The hemoglobin E thalassemias. *Cold Spring Harbor perspectives in medicine*, *2*(8), a011734.

Galanello, R., & Origa, R. (2010). Beta-thalassemia. *Orphanet journal of rare diseases*, *5*(1), 11.

Grech, L., Borg, K., & Borg, J. (2022). Novel therapies in β-thalassemia. British Journal of Clinical Pharmacology, 88(6), 2509-2524.

Greer, J. P., et al. (2018). Wintrobe's clinical hematology (14th ed.). Wolters Kluwer.

Hoffbrand, A. V., & Moss, P. A. H. (2016). Thrombosis 2: treatment. *Hoffbrand's Essential Haematology. 7th ed. Oxford, UK: Wiley Blackwell*, 311-320.

Hoffbrand, A. V., & Moss, P. A. H. (2019). Essential haematology (7th ed.). Wiley-Blackwell.

Hoffbrand, A. V., Moss, P. A. H., & Pettit, J. E. (2019). Color atlas of clinical hematology. Wiley-Blackwell.

Hossain, S., & Batcha, M. S. (2021). A Scientometric analysis and visualization on beta thalassemia research at global perspectives. Journal of Hospital Librarianship, 21(4), 391-404.

Kwiatkowski, D. P. (2005). How malaria has affected the human genome. Annual Review of Genomics and Human Genetics, 6, 397–425.

Makis, A., Hatzimichael, E., Papassotiriou, I., & Voskaridou, E. (2016). 2017 Clinical trials update in new treatments of β-thalassemia. American journal of hematology, 91(11), 1135-1145.

Modell, B., & Darlison, M. (2008). Global epidemiology of haemoglobin disorders. Bulletin of the World Health Organization, 86(6), 480–487.

Musallam, K. M., Rivella, S., Vichinsky, E., & Rachmilewitz, E. A. (2012). Non-transfusion-dependent thalassemias. Haematologica, 97(11), 1663–1671.

Nienhuis, A. W., & Persons, D. A. (2021). Gene therapy for the β-hemoglobinopathies. Molecular Therapy, 29(11), 3160–3170.

Origa, R. (2017). Beta-thalassemia. Genetics in Medicine, 19(6), 609–619.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Payen, E. (2022). Efficacy and safety of gene therapy for β-thalassemia. N Engel J Med, 386(5), 488-90.

Robbins, S. L., Kumar, V., Abbas, A. K., Fausto, N., & Aster, J. C. (2010). Robbins and Cotran pathologic basis of disease. *(No Title)*.

Rund, D., & Rachmilewitz, E. (2005). Beta-thalassemia. New England Journal of Medicine, 353(11), 1135–1146.

Taher, A. T., Musallam, K. M., & Cappellini, M. D. (2009). Thalassaemia intermedia: an update. *Mediterranean journal of hematology and infectious diseases*, *1*(1), e2009004.

Taher, A. T., Musallam, K. M., & Cappellini, M. D. (2018). β-Thalassemias. New England Journal of Medicine, 378(8), 727–743.*

Taher, A. T., Musallam, K. M., & Cappellini, M. D. (2023). Guidelines for the Management of Non-Transfusion-Dependent β-Thalassaemia [Internet].

Taher, A. T., Musallam, K. M., Inati, A., & Cappellini, M. D. (2009). Complications and management of β-thalassemia intermedia. Mediterranean Journal of Hematology and Infectious Diseases, 1(1), e2009004.*

Taher, A., & Cappellini, M. D. (2014). Guidelines for the management of transfusion dependent thalassaemia (TDT).

TB, C. (1925). A series of cases of splenomegaly in children with anemia and peculiar bone changes. *Trans Am Pediatr Soc*, *37*, 29-30.

Thein, S. L. (2013). The molecular basis of β-thalassemia. Cold Spring Harbor Perspectives in Medicine, 3(5), a011700.*

Vichinsky, E. (2018). Clinical manifestations of α- and β-thalassemia. Cold Spring Harbor Perspectives in Medicine, 3(5), a011726.*

Weatherall, D. J. (2010). The inherited diseases of hemoglobin are an emerging global health burden. *Blood, The Journal of the American Society of Hematology*, *115*(22), 4331-4336.